Therapeutic efficacy of new dimercaptosuccinic acid (DMSA) analogues in acute arsenic trioxide poisoning in mice.
The therapeutic efficacy of six newly synthesized analogues of dimercaptosuccinic acid (DMSA) was investigated in acute arsenic trioxide poisoning in mice. Meso-2,3-di(acetylthio)succinic acid (DATSA) and meso-2,3- di(benzoylthio)succinic acid (DBTSA) are analogues of DMSA with protected thiol groups ("prodrugs"), and DMDMS, DEDMS, DnPDMS, and DiPDMS are various di-esters of DMSA with methyl, ethyl, n-propyl, and isopropyl alcohols, respectively. Thirty minutes after s.c. injection of an LD80 of arsenic trioxide (65 mumol/kg) male NMRI mice were treated with a single equimolar dose (0.7 mmol/kg) of DMSA i.p. or one of the analogues i.p. or via gastric tube (i.g.). Control animals received arsenic trioxide and saline 30 min later. The survival rate was recorded for 30 days. All of the animals treated with DMSA i.p. survived and all controls died within 2 days. Administered i.g., DATSA and DBTSA increased the survival rate to 29% and 43%, and injected i.p. to 86%. Treatment with DMDMS i.p. and i.g., and with DEDMS, DnPDMS, and DiPDMS i.g. did not reduce lethality. Given i.p., DnPDMS increased the survival rate to 72%, and DEDMS and DiPDMS to 86%, respectively. To investigate the efficacy of the DMSA analogues in reducing the tissue content of arsenic, male NMRI mice received an s.c. injection of an LD5 of arsenic trioxide containing a tracer dose of 73-As(III) (42.5 mumol/kg body wt). Thirty minutes later, saline (controls) or a single equimolar dose (0.7 mmol/kg) of DMSA i.p., or one of the analogues i.p. or i.g. was administered. The arsenic content of various organs (blood, liver, kidneys, heart, lungs, spleen, small intestine, large intestine, brain, testes, skeletal muscle, and skin) at 30 min, 2 h, 4 h, 6 h, and 8 h after the arsenic injection was measured using a gamma counter.(ABSTRACT TRUNCATED AT 250 WORDS)
Kreppel
H
H
Institut für Pharmakologie und Toxikologie, Akademie des Sanitäs- und Gesundheitswesens der Bundeswehr, BSW, Garching, Germany.
Paepcke
U
U
Thiermann
H
H
Szinicz
L
L
Reichl
F X
FX
Singh
P K
PK
Jones
M M
MM
D000818:Animals; D000931:Antidotes / Q000008:administration & dosage / Q000494:pharmacology*; D001151:Arsenic / Q000493:pharmacokinetics; D020261:Arsenic Poisoning; D000077237:Arsenic Trioxide; D001152:Arsenicals; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007441:Intubation, Gastrointestinal; D008297:Male; D051379:Mice; D010087:Oxides / Q000506:poisoning*; D011041:Poisoning / Q000188:drug therapy; D004113:Succimer / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*
D000931:Antidotes; D001152:Arsenicals; D010087:Oxides; D004113:Succimer; D001151:Arsenic; D000077237:Arsenic Trioxide